Conversely, a Cas9-screen based approach in melanoma cells previously implicated PBRM1 loss enhanced cytokine expression, a more immunogenic TME and greater response to ICB24, and similarly we found that other tumor lineages did exhibit immunostimulatory effects following PBRM1 loss (Supplementary Fig. 4). This evidence concerns the gene PBRM1 and melanoma.